angiotensin IV raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-05 and is reviewed periodically as new material appears.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
The heart is composed of two atria and two ventricles. The primary purpose of the atria is to allow uninterrupted venous blood flow to the heart during ventricular systole. This allows enough blood to get into the ventricles during atrial systole. Consequently, the atria allow a cardiac output roughly 75% greater than would be possible without them. The purpose of the ventricles is to pump blood to the lungs through the right ventricle and to the rest of the body through the left ventricle. The heart has an electrical conduction system to control the contraction and relaxation of the muscles. It starts in the sinoatrial node traveling through the atria causing them to pump blood into the ventricles. It then travels to the atrioventricular node, which makes the signal slow down slightly allowing the ventricles to fill with blood before pumping it out and starting the cycle over again. Coronary artery disease is the leading cause of death worldwide, making up 16% of all deaths. It is caused by the buildup of plaque in the coronary arteries supplying the heart, eventually the arteries may become so narrow that not enough blood is able to reach the myocardium, a condition known as myocardial infarction or heart attack, this can cause heart failure or cardiac arrest and eventually death. Risk factors for coronary artery disease include obesity, smoking, high cholesterol, high blood pressure, lack of exercise and diabetes. Cancer can affect the heart, though it is exceedingly rare and has usually metastasized from another part of the body such as the lungs or breasts.
In genetics, the Ka/Ks ratio, also known as ω or dN/dS ratio, is used to estimate the balance between neutral mutations, purifying selection and beneficial mutations acting on a set of homologous protein-coding genes. It is calculated as the ratio of the number of nonsynonymous substitutions per non-synonymous site (Ka), in a given period of time, to the number of synonymous substitutions per synonymous site (Ks), in the same period. The latter are assumed to be neutral, so that the ratio indicates the net balance between deleterious and beneficial mutations. Values of Ka/Ks significantly above 1 are unlikely to occur without at least some of the mutations being advantageous. If beneficial mutations are assumed to make little contribution, then Ka/Ks estimates the degree of evolutionary constraint.
Adrenocorticotropic hormone (ACTH; also adrenocorticotropin, corticotropin) is a polypeptide tropic hormone produced by and secreted by the anterior pituitary gland. It is also used as a medication and diagnostic agent. ACTH is an important component of the hypothalamic-pituitary-adrenal axis and is often produced in response to biological stress (along with its precursor corticotropin-releasing hormone from the hypothalamus). Its principal effects are increased production and release of cortisol and androgens by the zona fasciculata and zona reticularis, respectively. ACTH is also related to the circadian rhythm in many organisms. Deficiency of ACTH is an indicator of secondary adrenal insufficiency (suppressed production of ACTH due to an impairment of the pituitary gland or hypothalamus, cf. hypopituitarism) or tertiary adrenal insufficiency (disease of the hypothalamus, with a decrease in the release of corticotropin releasing hormone (CRH)). Conversely, chronically elevated ACTH levels occur in primary adrenal insufficiency (e.g. Addison's disease) when adrenal gland production of cortisol is chronically deficient. In Cushing's disease, a pituitary tumor leads to excessive production of ACTH, which stimulates the adrenal cortex to produce high levels of cortisol.
No evidence for lawrencium being volatile was obtained and the lower limit for the enthalpy of adsorption of lawrencium on quartz or platinum was significantly higher than the estimated value for the s2p configuration.
== Side effects == A press release by GlaxoSmithKline in February 2007 noted that there is a greater incidence of fractures of the upper arms, hands and feet in female diabetics given rosiglitazone compared with those given metformin or glyburide. The information was based on data from the ADOPT trial. Following release of this statement, Takeda Pharmaceutical Company, the developer of pioglitazone (sold as Actos in many markets) admitted that it has similar implications for female patients. The risk of hypoglycemia is low in the absence of other drugs that lower blood glucose. Pioglitazone can cause fluid retention and peripheral edema. As a result, it may precipitate congestive heart failure (which worsens with fluid overload in those at risk). It may cause anemia. Mild weight gain is common due to increase in subcutaneous adipose tissue. In studies, patients on pioglitazone had an increased proportion of upper respiratory tract infection, sinusitis, headache, myalgia and tooth problems. Chronic administration of the drug has led to occasional instances of cholestatic hepatitis, reversible upon drug discontinuation. On 30 July 2007, an Advisory Committee of the Food and Drug Administration concluded that the use of rosiglitazone for the treatment of type 2 diabetes was associated with a greater risk of "myocardial ischemic events" when compared to placebo, but when compared to other diabetes drugs, there was no increased risk. Pioglitazone is currently being reviewed.
Sources: en.wikipedia.org
The Forestry Corps can trace its lineage to the Armed Forest Protection Battalions (Chinese: 武装护林大队); There were a total of four battalions; Each of the Hejiang, Songjiang, Longjiang and Jilin provinces consisted of one Armed Forest Protection Battalion. Founded on 25 August 1948, these units were created to conduct counterinsurgency operations against Japanese/Collaborator holdouts (This role was also later expanded to KMT holdouts after the Chinese Civil War), bandits and triads in Northeast China, which would often raid local villages and commit acts of arson, causing wildfires. At the time of establishment, each had 960 soldiers (3840 soldiers, all battalions combined). The Armed Forest Protection Battalions would often disguise themselves as hunters during recon, and used Cavalry tactics. By 16 October 1950, each battalion had 1600 soldiers (6400 Soldiers total). According to archives, by 1952, the Armed Forest Protection Battalions had killed a total of 6 KMT and American spies along with capturing a total of 46 spies, 34 triad members and 71 illegal migrants along with 68 firearms, multiple tens of thousand rounds of ammunition, multiple kilograms of drugs and prevented a total of 7 vandalism incidents. On 11 May 1953, the Armed Forest Protection Battalions were transferred to the People's Economic Police and renamed to the Forest Protection Police (Chinese: 护林警察队). Its task was to patrol forests, prevent illegal entry of protected areas and to serve as lookouts for forest fires.
=== Social organization === A study by Richard H.R. Harper, involving two laboratories, will help elucidate the concept of social organization in laboratories. The main subject of the study revolved around the relationship between the staff of a laboratory (researchers, administrators, receptionists, technicians, etc.) and their Locator. A Locator is an employee of a Laboratory who is in charge of knowing where each member of the laboratory currently is, based on a unique signal emitted from the badge of each staff member. The study describes social relationships among different classes of jobs, such as the relationship between researchers and the Locator. It does not describe the social relationship between employees within a class, such as the relationship between researchers. Through ethnographic studies, one finding is that, among the personnel, each class (researchers, administrators...) has a different degree of entitlement, which varies per laboratory. Entitlement can be both formal or informal (meaning it is not enforced), but each class is aware and conforms to its existence. The degree of entitlement, which is also referred to as a staff's rights, affects social interaction between staff. By looking at the various interactions among staff members, we can determine their social position in the organization. As an example, administrators, in one lab of the study, do not have the right to ask the Locator where the researchers currently are, as they are not entitled to such information. On the other hand, researchers do have access to this type of information.
== Adverse effects == The most common adverse effects are headache, hypothyroidism, cardiac conduction changes, gastrointestinal reactions (including cramps, nausea/vomiting and diarrhoea or constipation), gallstones, reduction of insulin release, hyperglycemia or sometimes hypoglycemia, and (usually transient) injection site reactions. Slow heart rate, skin reactions such as pruritus, hyperbilirubinemia, hypothyroidism, dizziness and dyspnoea are also fairly common (more than 1%). Rare side effects include acute anaphylactic reactions, pancreatitis and hepatitis. Some studies reported alopecia in those who were treated by octreotide. Rats which were treated by octreotide experienced erectile dysfunction in a 1998 study. A prolonged QT interval has been observed, but it is uncertain whether this is a reaction to the medication or the result of an existing illness.
== Redistribution == Highly lipid-soluble drugs given by intravenous or inhalation methods are initially distributed to organs with high blood flow. Later, less vascular but more bulky tissues (such as muscle and fat) take up the drug—plasma concentration falls and the drug is withdrawn from these sites. If the site of action of the drug was in one of the highly perfused organs, redistribution results in termination of the drug action. The greater the lipid solubility of the drug, the faster its redistribution will be. For example, the anaesthetic action of thiopentone is terminated in a few minutes due to redistribution. However, when the same drug is given repeatedly or continuously over long periods, the low-perfusion and high-capacity sites are progressively filled up and the drug becomes longer-acting.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.